Highest-materiality recent filing
Arcus Q2 net loss $91M, revenue $41M; casdatifan pipeline advances with new collaborations
Net loss of $91M in Q2 2026 vs. $0 in Q2 2025; revenue fell to $41M from $160M.
Arcus Q1 net loss $128M, cash $876M; discontinues Phase 3 STAR-121 in NSCLC
Net loss $128M for Q1 2026 vs $112M Q1 2025; revenue $17M down from $28M.
Arcus discontinues Phase 3 STAR-121 NSCLC trial; Gilead lets option rights lapse
STAR-121 evaluating domvanalimab + zimberelimab + chemo vs pembro + chemo in 1L metastatic NSCLC stopped by IDMC for futility.
Arcus Biosciences reports Q4 net loss $106M; casdatifan shows 45% cORR in late-line kidney cancer
Q4 2025 net loss $106M vs $94M YoY; revenue $33M; cash, equivalents & marketable securities $1.0B.
Arcus Biosciences amends loan agreement to access up to $150M tied to clinical and FDA milestones
First Amendment to Loan and Security Agreement with Hercules Capital dated December 18, 2025.
Arcus ends Phase 3 STAR-221 domvanalimab study on futility; no OS benefit
Phase 3 STAR-221 of domvanalimab + zimberelimab + chemo vs nivolumab + chemo stopped for futility after IDMC review.
Arcus Biosciences closes public offering of 15.76M shares, net proceeds ~$269.7M
Sold 15,755,000 shares at $18.25 per share including full exercise of underwriters' option.
Net loss of $135M for Q3 2025 vs $92M in Q3 2024; revenue $26M vs $48M.
Arcus Bio's EDGE-Gastric Ph2 shows median OS 26.7 months; ORR 59%
Median OS 26.7 months (90% CI: 18.4, NE) for all patients (n=41); PD-L1 high subgroup NE.
ARC-20 pooled analysis (n=121) in ccRCC: 31% confirmed ORR [95% CI 23-40], median PFS 12.2 mo (9.4-20.6).
Cash, cash equivalents & marketable securities: $927M at June 30, 2025 (Dec 31, 2024: $992M).
Arcus reports 46% confirmed ORR for casdatifan + cabozantinib in ccRCC post-immunotherapy
Phase 1/1b ARC-20 interim analysis shows 46% cORR (11/24) per RECIST v1.1; median follow-up 5.3 months.
Arcus Q1 net loss widens to $112M; cash $1.0B; casdatifan Phase 3 to start Q2
Revenue fell to $28M from $145M YoY; full-year 2025 revenue guidance $75M-$90M.
Arcus Q4 2024 net loss $94M; casdatifan shows best-in-class potential in ccRCC
Revenue $36M for Q4 2024 ($31M Q4 2023); net loss widened to $94M from $81M.
Arcus Biosciences raises ~$141.6M in public offering of 13.6M shares at $11.00/share
Offered 13,636,364 shares at $11.00/share, yielding ~$141.6M net proceeds after expenses.
Arcus reports $992M cash; Gilead opts out of casdatifan; ARC-20 data shows ORR 25-33%
Preliminary cash, cash equivalents and marketable securities of $992M as of Dec 31, 2024.
Arcus Q3 net loss $92M; casdatifan shows 34% ORR, domvanalimab 36% risk reduction
Net loss $92M vs $71M YoY; revenue $48M (up from $32M) on $41M license and development services.
Arcus Biosciences secures up to $250M term loan facility from Hercules Capital; initial $50M funded
Initial $50M funded; additional $50M available at company's option through Jun 2025 and another $50M through Mar 2026; final $100M at lenders' option.
Arcus reports Q2 2024 net loss $93M, cash $1.0B; casdatifan data due Q4
Revenue $39M (up from $29M in Q2 2023); net loss $93M vs $75M year-over-year.
Median PFS of 12.9 months (95% CI 9.8–13.8) across 41 patients in the domvanalimab+zimberelimab+chemo arm.
ARC-9 interim analysis: EZFB combo improves PFS (HR 0.27) and OS (HR 0.37) vs regorafenib in 3L mCRC
Cohort B (n=112) met primary endpoint: PFS HR 0.27 (p<0.0001), median 6.2 vs 2.1 months.
Revenue $145M vs $25M YoY, including $135M license revenue from Gilead collaboration amendments.
Net loss of $81M in Q4 2023 ($307M full year); revenue $31M Q4 2023 vs $34M Q4 2022.
Gilead invests $320M in Arcus at $21/share; collaboration amended to accelerate anti-TIGIT program
Gilead purchases 15.2M shares for $320M at $21/share, increasing ownership to 33%.
Arcus Biosciences Q3 net loss $71M; cash $950M; domvanalimab and AB521 updates
Net loss of $71M in Q3 2023 vs $65M in Q3 2022; R&D expenses rose to $82M from $77M.
Arcus Q2 net loss $75M, cash $1.0B; deprioritizes etrumadenant in mCRPC
Cash $1.0B vs $1.1B at Dec 2022; 2023 cash burn guided $290-325M; funding into 2026.
Arcus Biosciences sells 1.01M shares to Gilead at $19.26 per share under amended purchase agreement
Gilead to purchase 1,010,000 shares of Arcus common stock at $19.26 per share.
Arcus ARC-7 Phase 2 data: domvanalimab arms reduce PFS risk 28-33% in NSCLC
Doublet (domvanalimab+zimberelimab) showed 33% PFS risk reduction (HR 0.67) vs zimberelimab monotherapy in PD-L1≥50% NSCLC.
Arcus gets $35M upfront from Gilead to collaborate on up to 4 inflammatory disease targets
Upfront payment of $35M from Gilead Sciences under Amendment No. 2 to existing collaboration.
Arcus Q1 net loss $80M, cash $1.0B; multiple Ph3 domvanalimab trials enrolling
Revenue $25M (up from $18M YoY); net loss $80M vs $68M in Q1 2022.
Arcus Biosciences Q4 net loss $67M; ARC-7 domvanalimab combo doubles PFS to 12 months
Q4 2022 net loss $67M vs net income $280M in Q4 2021; full-year net loss $267M vs net income $53M.
Arcus ARC-7 Phase 2: domvanalimab doublet cuts progression risk 45% vs. zimberelimab
Median PFS: doublet 12.0 mo, triplet 10.9 mo vs. monotherapy 5.4 mo (HR 0.55 and 0.65).
Arcus reports positive Phase 2 interim results for domvanalimab combo in NSCLC
Fourth interim analysis of ARC-7 trial (n=133) shows domvanalimab-containing arms differentiate from zimberelimab monotherapy.
Q3 revenue $33.6M (up from $9.5M); net loss $64.9M vs $78.0M prior year.
Arcus and Gilead extend share lockup to July 2023, agree to register resale shares
Lockup on Gilead's Arcus shares extended by one year to July 13, 2023, from original two-year term ending May 2022.
Cash, cash equivalents and investments $1,271.1M at June 30, 2022, up from $681.3M at Dec 2021, driven by $725M Gilead payment.
Arcus Q1 net loss $68M; ARC-7 domvanalimab arms continue to differentiate
Cash $1.34B, up from $681M due to $725M from Gilead in Jan 2022; funding into 2026.
Q4 2021 revenue $354.5M (vs $9.5M Q4 2020) primarily from Gilead license revenue; full-year revenue $382.9M.
Arcus closes Gilead amendment; receives $725M option fees for 3 programs
Closed amendment to Option, License and Collaboration Agreement with Gilead on Dec 21, 2021.
Gilead exercises options on three Arcus programs for $725M; co-development and profit sharing
Gilead paid $725M in option fees to exercise rights to three Arcus programs: anti-TIGIT, adenosine antagonist, and CD73.
On February 6, 2025, the Board appointed Dietmar Berger M.D., Ph.D., as a Class II director to fill the vacancy left by Dr. Parsey's resignation.
On February 6, 2025, in connection with his departure from Gilead Sciences, Inc. (“Gilead”), Merdad Parsey, M.D., Ph.D., resigned as a member of Arcus Biosciences, Inc.’s (“Arcus”) Board of Directors (the “Board”), effective upon the appointment of Gilead’s new director designee pursuant to the Amended and Restated Investor Rights Agreement dated January 29, 2024 by and between Arcus and Gilead.
Richard Markus, M.D., Ph.D. has been appointed as the Company’s Chief Medical Officer, effective January 31, 2025
Dimitry Nuyten, M.D., Ph.D. will depart from the Company on January 31, 2025
the Board appointed Johanna Mercier to the Board as a Class II director
Dr. Jaen and Ms. Jarrett resigned from the Board
Dr. Jaen and Ms. Jarrett resigned from the Board
Concurrent with Mr. Azoy’s appointment as the Company’s Principal Accounting Officer, Robert C. Goeltz II, the Company’s Chief Financial Officer (and in such role was the Company’s Principal Financial Officer), ceased to function as the Company’s Principal Accounting Officer.
On March 9, 2023, the Board of Directors (the “Board”) of Arcus Biosciences, Inc. (the “Company”) appointed Alexander Azoy to serve as the Company’s Principal Accounting Officer.
On August 10, 2021, the Board appointed Linda Higgins, Senior Vice President of Research, External Innovation at Gilead, as a Class III director to fill the vacancy left by Dr. Quigley’s resignation.
Michael Quigley, Ph.D., resigned as a member of Arcus Biosciences, Inc.’s Board of Directors, effective upon the appointment of Gilead’s new director designee
On August 3, 2021, the Board of Directors of Arcus Biosciences, Inc. appointed Nicole Lambert to the Board as a Class II Director.
Max materiality 0.85 · Median 0.70 · Most common event other_material